NanoKnife Offers Promising Treatment Option for Locally ... | 合法醫療器材資訊網

Aprospectivemulticenterstudyof54patientswithinitiallyunresectablepancreascancercomparedIREtopropensitymatchedcontrolsundergoingstandard ...

by Boris Kuvshinoff II, MD, MBA[1] Chief Medical Officer, Professor of Oncology

Patients with localized (stages I and II) pancreatic adenocarcinoma are typically offered surgical removal to give the best chance for long-term survival. Unfortunately, only about 20% of patients fall within these stage categories, and some of these are probably better characterized as "borderline resectable." A higher number of patients, up to 30-40%, will present with locally advanced (stage III) disease not amenable to surgical resection. This patient group typically undergoes chemotherapy or chemoradiation with an anticipated median survival of 10-12 months.

For patients with this more advanced disease, we have had some success in extending survival using NanoKnife IRE (Irreversible Electroporation). NanoKnife is a minimally invasive, probe-based technology that...